🚀 LandBridge Expands in New Mexico; Applied Industrial Acquires Hydradyne, and J&J Advances TREMFYA® for Ulcerative Colitis 📈
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, StockNews.AI identified and published 196 successful event alerts across multiple sectors — nearly four times the number from the previous week!
Notably, 39 of these alerts featured price changes exceeding 10%, with the majority signaling bullish trends 📈.
*Data Captured Between 11/18 00:00am - 11/22 11:00 am EDT.
On November 18, we have launched a new navigation, watchlist, and alert list to help you navigate your portfolio and track your AI alerts effortlessly! Join StockNews.AI today to make your investment simple!
Top 3 news you can’t miss for today, 11/22.
Business Wire
BullishLongTermLBM&A
LandBridge Closes Acquisition of ~5,800 Surface Acres in Lea County, New Mexico and Increases 2025 Guidance
- LandBridge acquired 5,800 acres in Lea County, increasing its Delaware Basin presence.
- Total acquisitions in Q4 2024 reach approximately 53,080 acres, enhancing revenue potential.
- Expected FCF accretion of over 20% per common share post-acquisitions.
- Increased 2025 Adjusted EBITDA guidance to between $170 million and $190 million.
- Funding through private placements and debt, with management maintaining 70% ownership.
Business Wire
VeryBullishLongTermAITM&A
Applied Industrial Technologies to Acquire Hydradyne, LLC
- AIT acquires Hydradyne, enhancing fluid power capabilities and market presence.
- Hydradyne projected to add $260 million in sales and $30 million in EBITDA.
- Acquisition strengthens AIT's position in U.S. Southeast, aiding growth potential.
- Synergies expected to improve EPS within 12 months post-acquisition.
- Hydradyne's advanced service capabilities align with AIT's strategic goals.
PRNewsWire
BullishLongTermJNJFDA Approval
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
- TREMFYA® received FDA approval for ulcerative colitis treatment.
- The ASTRO study met its primary endpoint for clinical remission.
- TREMFYA® is the first IL-23 inhibitor for SC administration.
- Recent approvals increase JNJ's market position in IBD treatments.
- Upcoming presentations will share further data on TREMFYA®.
Here’re the top 5 most-surged stocks this week.
*Penny stocks are not included in the list.
PRNewsWire
BearishShortTerm -42.19%CATOEarnings
CATO REPORTS 3Q RESULTS
- Cato Corporation reported a net loss of $15.1 million in Q3 2024.
- Sales dropped by 8% compared to Q3 2023 at $144.6 million.
- Same-store sales decreased by 3%, indicating declining customer traffic.
- Higher costs due to supply chain issues affected gross margin, now at 28.8%.
- Company plans to manage expenses amid ongoing challenges and store closures.
Accesswire
BullishLongTerm 28.05%BDRXM&A
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
- Biodexa acquires eRapa for treating familial adenomatous polyposis (FAP).
- Phase 3 study funded by a $17 million grant; NDA expected in three years.
- eRapa shows promising Phase 2 results with potential peak sales of $1 billion.
- Biodexa plans further studies on tolimidone for Type 1 diabetes.
- Positive Phase 1 results for MTX110 in recurrent glioblastoma reported.
PRNewsWire
VerybullishLongTerm 26.32%NGVCEarnings
Natural Grocers by Vitamin Cottage Announces Fiscal 2024 Fourth Quarter and Full Year Results
- Net sales increased 9.3% to $322.7 million in Q4 FY 2024.
- Net income surged 53.2% to $9.0 million, EPS reached $0.39.
- Adjusted EBITDA rose 40.5% to $22.6 million in Q4 FY 2024.
- Quarterly dividend increased by 20% to $0.12 per share.
- Company anticipates 4-6 new stores and sales growth in FY 2025.
Business Wire
BullishLongTerm 20.19%OKLOM&A
Atomic Alchemy, Oklo's Proposed Acquisition Target, Signs MOU with Zeno Power to Provide Fuel for Commercial Radioisotope Power Systems
- Oklo's acquisition of Atomic Alchemy progresses with an MOU signed with Zeno Power.
- The collaboration will enhance radioisotope supply for space and defense applications.
- Atomic Alchemy aims to build a scalable U.S. radioisotope production facility.
- Zeno Power has secured over $65 million in NASA and defense contracts.
- Oklo's recycling processes will support the supply of crucial radioisotopes.
Business Wire
BullishLongTerm 19.76%VSTSEarnings
Vestis Reports Fourth Quarter and Fiscal 2024 Results
- Fiscal 2024 revenue fell 0.7%, slightly missing expectations.
- Fourth quarter revenue dropped 4.4%, reflecting lower pricing and lower volumes.
- Management expects revenue and Adjusted EBITDA growth in fiscal 2025.
- Net income for Q4 declined significantly to a loss of $2.3 million.
- A new $250 million A/R securitization facility aims to improve liquidity.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Want something new? Choose one for the next newsletter topic✨ Poll closes on every Friday at 11:59pm! |
|
Login or Subscribe to participate in polls. |
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply